arrow
A

Anthony De Soyza

newcastle university - uk
H-index:68
Citation Count:2.0万
Views:0

Biography

No content for now.

Education

No content for now.

Work Experience

No content for now.

Honors & Awards

No content for now.

Investigating prognostic classifications of pre-existing multiple long-term conditions for health outcomes one-year after COVID-19 hospitalisation: a UK prospective observational study

探究COVID-19住院后一年内,预先存在的多种长期疾病的预后分类对健康结局的影响:一项英国前瞻性观察研究

2026-04-090
OAAI
The Worldwide Puzzle of Bronchiectasis Etiology in Adults

成人支气管扩张病因学的全球谜题

2025-12-040
PRE
Improving patient engagement in clinical trials: Launching the BOAT trial with key stakeholders

提升临床试验中的患者参与度:与关键利益相关方启动BOAT试验

2025-12-010
OA
Clinical Burden of People with Symptomatic and Exacerbating COPD While on Triple Inhaled Therapy

有症状和加重的COPD患者在三联吸入疗法期间的临床负担

2025-10-010
OAAI
Rising to the challenges of research in multiple long-term conditions: health and social care research ecosystem approaches

应对多种长期病症研究的挑战:健康和社会护理研究生态系统的途径

2025-09-140
OA
Hypertonic Saline or Carbocisteine in Bronchiectasis

支气管扩张中的高渗盐水或羧甲司坦

2025-09-011
PRE
Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational study

症状、未来急性加重的风险以及对长期大环内酯治疗的反应:一项观察性研究

2025-08-270
OAAI
An Observational, Cross-Sectional Study to Investigate Whether Room Air Ventilators, Used in the Community Setting, Are Colonised by Potential Airborne Pathogens (IPAP Study)
2025-02-110
OAAI
Airway total bacterial density, microbiota community composition and relationship with clinical parameters in bronchiectasis

支气管扩张的气道总细菌密度,微生物群落组成及其与临床参数的关系

2025-01-010
PRE
Perception of COPD control by physicians managing symptomatic exacerbating patients receiving inhaled triple therapy: a real-world multi-country 2022 survey
2024-10-300
PRE
Unveiling Cystic fibrosis in Non-CF bronchiectasis patients: Insights from the European Multicentre Bronchiectasis Audit and Research Collaboration(EMBARC) Registry
2024-10-300
PRE
Use of bronchodilators in bronchiectasis: data from EMBARC
2024-10-300
PRE
Sputum Azurocidin-1 is a marker of disease severity and microbiome dysbiosis in adult bronchiectasis, and increases in response to Rhinovirus challenge in COPD.
2024-10-300
PRE
Post TB Bronchiectasis:a distinct phenotype
2024-10-300
PRE
Functional antibody response to pneumococcal (PNE) and Haemophilus influenzae type B (HiB) vaccination in bronchiectasis (BE): data from the EMBARC registry
2024-10-300
PRE
Cardiovascular events in patients with bronchiectasis: Data from the European Bronchiectasis Registry (EMBARC)
2024-10-300
PRE
Characterising patients with bronchiectasis and persistently negative sputum cultures: data from the European Bronchiectasis Registry EMBARC.
2024-10-300
PRE
Characteristics of exacerbating COPD patients with productive cough and on inhaled triple therapy, by smoking status: a real-world multi-country study
2024-10-300
PRE
Highly symptomatic patients have an increased risk of exacerbations and benefit from long-term macrolide treatment in Bronchiectasis
2024-10-300
PRE
ANNUALIZED EXACERBATION RATE IN PATIENTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS BY PRESPECIFIED SUBGROUPS IN THE PH3, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED ASPEN TRIAL
CHEST
IF8.6
2024-10-010
PRE